Up to 500 roles at Idorsia are at risk as the Swiss biotech tries to halve its cash burn while it waits for its approved insomnia treatment Quviviq to pay off. Facing a “challenging financial ...

Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Burn Ointment - Market Insights, Competitive Landscape, and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

(the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.